These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 29162455

  • 1. Synthesis and biological evaluation of water-soluble derivatives of chiral gossypol as HIV fusion inhibitors targeting gp41.
    Yang J, Li LL, Li JR, Yang JX, Zhang F, Chen G, Yu R, Ouyang WJ, Wu SW.
    Bioorg Med Chem Lett; 2018 Jan 01; 28(1):49-52. PubMed ID: 29162455
    [Abstract] [Full Text] [Related]

  • 2. Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1.
    An T, Ouyang W, Pan W, Guo D, Li J, Li L, Chen G, Yang J, Wu S, Tien P.
    Antiviral Res; 2012 Jun 01; 94(3):276-87. PubMed ID: 22426469
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41.
    Jiang S, Tala SR, Lu H, Zou P, Avan I, Ibrahim TS, Abo-Dya NE, Abdelmajeid A, Debnath AK, Katritzky AR.
    Bioorg Med Chem Lett; 2011 Nov 15; 21(22):6895-8. PubMed ID: 21978673
    [Abstract] [Full Text] [Related]

  • 4. Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41.
    Wang Y, Lu H, Zhu Q, Jiang S, Liao Y.
    Bioorg Med Chem Lett; 2010 Jan 01; 20(1):189-92. PubMed ID: 19932616
    [Abstract] [Full Text] [Related]

  • 5. Small molecule fusion inhibitors: design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41.
    He XY, Lu L, Qiu J, Zou P, Yu F, Jiang XK, Li L, Jiang S, Liu S, Xie L.
    Bioorg Med Chem; 2013 Dec 01; 21(23):7539-48. PubMed ID: 23673219
    [Abstract] [Full Text] [Related]

  • 6. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
    Jiang S, Lu H, Liu S, Zhao Q, He Y, Debnath AK.
    Antimicrob Agents Chemother; 2004 Nov 01; 48(11):4349-59. PubMed ID: 15504864
    [Abstract] [Full Text] [Related]

  • 7. Synthesis and antiviral activities of novel gossypol derivatives.
    Yang J, Zhang F, Li J, Chen G, Wu S, Ouyang W, Pan W, Yu R, Yang J, Tien P.
    Bioorg Med Chem Lett; 2012 Feb 01; 22(3):1415-20. PubMed ID: 22226654
    [Abstract] [Full Text] [Related]

  • 8. Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41.
    Zhou G, Wu D, Snyder B, Ptak RG, Kaur H, Gochin M.
    J Med Chem; 2011 Oct 27; 54(20):7220-31. PubMed ID: 21928824
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and anti-H5N1 activity of chiral gossypol derivatives and its analogs implicated by a viral entry blocking mechanism.
    Yang J, Chen G, Li LL, Pan W, Zhang F, Yang J, Wu S, Tien P.
    Bioorg Med Chem Lett; 2013 May 01; 23(9):2619-23. PubMed ID: 23538114
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. An amphiphilic conjugate approach toward the design and synthesis of betulinic acid-polyphenol conjugates as inhibitors of the HIV-1 gp41 fusion core formation.
    Liu Y, Ke Z, Wu KY, Liu S, Chen WH, Jiang S, Jiang ZH.
    ChemMedChem; 2011 Sep 05; 6(9):1654-64. PubMed ID: 21688394
    [Abstract] [Full Text] [Related]

  • 14. Design, synthesis, and evaluation of indole compounds as novel inhibitors targeting Gp41.
    Zhou G, Wu D, Hermel E, Balogh E, Gochin M.
    Bioorg Med Chem Lett; 2010 Mar 01; 20(5):1500-3. PubMed ID: 20153190
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Anti-HIV-1 Activity Prediction of Novel Gp41 Inhibitors Using Structure-Based Virtual Screening and Molecular Dynamics Simulation.
    Sepehri S, Saghaie L, Fassihi A.
    Mol Inform; 2017 Mar 01; 36(3):. PubMed ID: 27730744
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Covalent fusion inhibitors targeting HIV-1 gp41 deep pocket.
    Bai Y, Xue H, Wang K, Cai L, Qiu J, Bi S, Lai L, Cheng M, Liu S, Liu K.
    Amino Acids; 2013 Feb 01; 44(2):701-13. PubMed ID: 22961335
    [Abstract] [Full Text] [Related]

  • 19. A synthetic C34 trimer of HIV-1 gp41 shows significant increase in inhibition potency.
    Nomura W, Hashimoto C, Ohya A, Miyauchi K, Urano E, Tanaka T, Narumi T, Nakahara T, Komano JA, Yamamoto N, Tamamura H.
    ChemMedChem; 2012 Feb 06; 7(2):205-8. PubMed ID: 22247043
    [No Abstract] [Full Text] [Related]

  • 20. Synthesis, biophysical characterization, and anti-HIV-1 fusion activity of DNA helix-based inhibitors with a p-benzyloxyphenyl substituent at the 5'-nucleobase site.
    Tang Y, Han Z, Guo J, Tian Y, Liu K, Xu L.
    Bioorg Med Chem Lett; 2018 Jun 01; 28(10):1842-1845. PubMed ID: 29680665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.